Livagen: A Short Peptide Bioregulator with Reported Effects on Chromatin Decondensation

Research summary. Livagen (Lys-Glu-Asp-Ala) is a tetrapeptide member of the Khavinson short-peptide bioregulator family, closely related in design and provenance to other "Khavinson peptides" such as Epithalon, Vilon, Cortagen, and Pinealon. The published research programme on Livagen is centred on reports that the peptide can decondense lymphocyte chromatin and reactivate transcriptional activity in samples from aged donors. As with the broader bioregulator family, the primary supporting literature is concentrated in a single research programme and independent external validation remains limited; this should be a foreground consideration in any research-context use.

Molecular profile

• Sequence: Lys-Glu-Asp-Ala (KEDA)
• Molecular formula: C₁₈H₃₁N₅O₉
• Molecular weight: ~461.5 g/mol
• PubChem CID: 87919683
• CAS: 195875-84-4
• Family: Khavinson short-peptide bioregulators (alongside Epithalon, Vilon, Cortagen, Cartalax, Pinealon, Bronchogen, Cardiogen, Chonluten, others)

Mechanism of action

The mechanistic model proposed by the originating research programme is that short Khavinson peptides interact in a sequence-specific manner with double-stranded DNA, intercalating or binding within the minor groove and modulating chromatin condensation states. The published interpretation is that this interaction is sufficient to alter chromatin packaging on heterochromatic regions, "decondensing" inactive chromatin and re-enabling transcription of previously silenced genes. In the case of Livagen specifically, the model emphasises decondensation of chromatin in lymphocytes from aged donors, with concomitant reactivation of ribosomal gene activity and broader transcriptional remodelling.

This proposed mechanism — short-peptide-driven chromatin reorganisation — represents an unconventional and not widely accepted model in mainstream chromatin biology. Reproducibility outside the originating laboratory has been limited, and the structural-biology basis for sequence-specific tetrapeptide–DNA interactions of the proposed kind has not been independently established at the level conventionally expected for a chromatin-modifying class of compounds.

Preclinical research highlights

Lymphocyte chromatin reactivation. Cytogenetic studies from the originating research programme on cultured lymphocytes from aged donors have reported decondensation of facultative heterochromatin, reactivation of ribosomal gene activity (assessed by silver-staining of nucleolar organiser regions), and restoration of patterns more typical of younger-donor cells.

Comparative work alongside other Khavinson peptides. Livagen has been studied side-by-side with Epithalon, Vilon, and other family members, with reports that each peptide preferentially modulates expression in tissue compartments mapped to its proposed peptide-tissue specificity (gastrointestinal, immune, hepatic for Livagen).

Reported enkephalinase inhibition. Some publications attribute to Livagen an inhibitory effect on plasma enzymes that degrade enkephalin peptides, with consequent reported modulation of nociceptive processing in rodent models. This line of work is more limited and the effect size and mechanism have not been independently corroborated at scale.

Immune-cell phenotype changes. Reports include shifts in lymphocyte subset profiling and proliferation responses in aged-donor samples, framed within the broader bioregulator hypothesis.

Current research status

Livagen is an investigational research peptide. It is not an FDA-approved drug. The peer-reviewed literature is dominated by publications from the originating Russian research programme (St Petersburg Institute of Bioregulation and Gerontology), and independent replication outside that programme is limited. For research-context interpretation, this constitutes the most important caveat: the mechanistic and translational claims associated with Livagen rest on a body of work that has not been broadly validated in external laboratories at the depth that would be expected for a novel chromatin-modifying agent.

For research-supplier contexts, Livagen is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Livagen is a Lys-Glu-Asp-Ala tetrapeptide and a member of the Khavinson short-peptide bioregulator family.
• The mechanistic model centres on sequence-specific chromatin decondensation in lymphocytes from aged donors and reactivation of silenced gene expression.
• Reported effects extend to ribosomal gene activity, immune-cell function, and putative enkephalinase inhibition.
• The supporting literature is concentrated in a single research programme; independent external validation is limited and this should be a foreground consideration.
• Livagen is not an FDA-approved drug; identity and purity verification are basic prerequisites for any research handling.

References

1. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel, 2005.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Livagen is not an FDA-approved drug. It is not intended for self-administration, and any research-context handling should be conducted by qualified personnel within an appropriate institutional setting and in compliance with applicable regulatory requirements. Nothing in this article constitutes medical advice or a recommendation for use.